DigmBio
Latest round
- Series A
Last raised
- Mar 2025
Total raised
- $8.2M
Investors
- 7
About DigmBio
Based in South Korea and founded in 2020, DigmBio Inc. provides innovative therapies by combining scientific knowledge with practical experience. In March 2025, DigmBio Inc. Jeongmin Kim is leading the firm as CEO as of 2025. DigmBio’s focus is on developing innovative therapies in previously difficult or unaddressed medical areas. Their pipeline includes treatments aimed at a range of diseases, and they are actively engaged in research and development to bring new, viable solutions to market. The company showcases its work at major industry events, ensuring its innovative approach gains visibility within the pharmaceutical sector.
Who invested in DigmBio
7 investors across 1 round
See all investors in DigmBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 25, 2025
Amount
$8.2M
Investors
Questions about DigmBio
Who invested in DigmBio?
DigmBio has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has DigmBio raised?
DigmBio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did DigmBio last raise money?
DigmBio's most recent round on record is a Series A, in Mar 2025.
What does DigmBio do?
Based in South Korea and founded in 2020, DigmBio Inc.
Where is DigmBio headquartered?
DigmBio is headquartered in Seongnam-si, South Korea.
Which VCs invest in companies like DigmBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at DigmBio's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like DigmBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.